Publications by authors named "Gerhard Nehmiz"

Claim this Profile
S
Safety, tolerability, and pharmacokinetics of faldaprevir after single increasing doses in healthy subjects.
Chan-Loi Yong, Regina Sennewald, Gerhard Nehmiz, Anne-Marie Quinson, Fenglei Huang

Front Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian Phase II optimization for time-to-event data based on historical information.
Anja Bertsche, Frank Fleischer, Jan Beyersmann, Gerhard Nehmiz

Stat Methods Med Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.
Bengt I Eriksson, Zsolt Mikuska, Martin Feuring, Jean Amiral, Sebastian Haertter, Gerhard Nehmiz

Thromb Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials.
Anja Bertsche, Gerhard Nehmiz, Jan Beyersmann, Andrew P Grieve

Biom J· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
Rucha S Sane, Gerhard G Steinmann, Qihong Huang, Yongmei Li, Lalitha Podila, Gerhard Nehmiz

J Pharmacol Exp Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean-Pierre Zarski, Dominique Larrey, Gerhard Nehmiz

Antivir Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Paul A Reilly, Thorsten Lehr, Sebastian Haertter, Stuart J Connolly, Salim Yusuf, Gerhard Nehmiz

J Am Coll Cardiol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.
Dominique Larrey, Ansgar W Lohse, Christian Trepo, Jean-Pierre Bronowicki, Keikawus Arastéh, Gerhard Nehmiz

Antimicrob Agents Chemother· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Mark S Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Gerhard Nehmiz

Hepatology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Mark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, Tarik Asselah, Jean-Michel Pawlotsky, Gerhard Nehmiz

Hepatology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.
Sebastian Härtter, Regina Sennewald, Gerhard Nehmiz, Paul Reilly

Br J Clin Pharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren

Clin Pharmacol Drug Dev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the letter by Dr Chin and co-workers.
Sebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, Gerhard Nehmiz, Ute Lemke

Br J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
Sebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, Gerhard Nehmiz, Ute Lemke

Br J Clin Pharmacol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean-Pierre Zarski, Dominique Larrey, Gerhard Nehmiz

Gastroenterology· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.
Andreas Erhardt, Katja Deterding, Yves Benhamou, Markus Reiser, Xavier Forns, Gerhard Nehmiz

Antivir Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
Michael D Ezekowitz, Paul A Reilly, Gerhard Nehmiz, Timothy A Simmers, Rangadham Nagarakanti

Am J Cardiol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, Holger Hinrichsen, Yves Benhamou, Gerhard Nehmiz

Antivir Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Joachim Stangier, Bengt I Eriksson, Ola E Dahl, Lennart Ahnfelt, Gerhard Nehmiz

J Clin Pharmacol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Markus Reiser, Holger Hinrichsen, Yves Benhamou, Henk W Reesink, Heiner Wedemeyer, Gerhard Nehmiz

Hepatology· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
Holger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, Markus Reiser, Roel E Sentjens, Gerhard Nehmiz

Gastroenterology· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects.
Brian D Guth, Hans Narjes, Hans-Dieter Schubert, Paul Tanswell, Axel Riedel, Gerhard Nehmiz

Br J Clin Pharmacol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis